BMJ4d
Treatment of early oligoarticular psoriatic arthritis with apremilast: primary outcomes at week 16 from the FOREMOST randomised controlled trial
Objectives Oligoarticular psoriatic arthritis (PsA) is frequent but rarely studied. The objective was to assess the efficacy of apremilast in early oligoarticular PsA. Methods FOREMOST (NCT03747939) ...
BMJ16d
Correspondence on ‘EULAR recommendations for the management of systemic lupus erythematosus: 2023 update’ by Fanouriakis et al
We read with great interest the new EULAR guidelines1 for the management of systemic lupus erythematosus (SLE), and we appreciate the care taken in synthesising the newest research to advance best ...
BMJ16d
Protein kinase R is highly expressed in dermatomyositis and promotes interferon-beta-induced muscle damage
Objectives Dermatomyositis (DM) has been consistently linked to the type I interferon (IFN-I) pathway. However, the precise pathogenesis remains incompletely elucidated. We aimed to explore potential ...
BMJ3d
Gout: why is this curable disease so seldom cured?
3 Department of Rheumatology, University of Edinburgh, Centre for Molecular Medicine, Western General Hospital, Edinburgh, Scotland, UK 4 Department of Medicine, Rheumatology Section, Alicante ...
BMJ5d
Ultrasensitive serum interferon-α quantification during SLE remission identifies patients at risk for relapse
1 Sorbonne Université, Assistance Publique–Hôpitaux de Paris, Groupement Hospitalier Pitié–Salpêtrière, French National Referral Center for Systemic Lupus Erythematosus, Antiphospholipid Antibody ...
BMJ7d
Is the epidemiology of rheumatoid arthritis changing? Results from a population-based incidence study, 1985–2014
Objectives To examine trends in the incidence of rheumatoid arthritis (RA) from 2005 to 2014 overall and by serological status as compared with 1995–2004 and 1985–1994. Methods We evaluated RA ...
BMJ4d
Low-ratio somatic NLRC4 mutation causes late-onset autoinflammatory disease
Objectives We aim to investigate the genetic basis of a case of late-onset autoinflammatory disease characterised by arthritis, recurrent fever and skin rashes. Methods We performed whole-exome/genome ...
BMJ11d
Extracting immunological and clinical heterogeneity across autoimmune rheumatic diseases by cohort-wide immunophenotyping
Correspondence to Prof. Yukinori Okada, Department of Statistical Genetics, Osaka University School of Medicine Graduate School of Medicine, Suita, Osaka, Japan; yuki-okada{at}m.u-tokyo.ac.jp; Prof.
BMJ5d
AB1439 UPDATE OF THE EULAR POINTS TO CONSIDER FOR USE OF ANTIRHEUMATIC DRUGS IN REPRODUCTION, PREGNANCY AND LACTATION
6 Skaggs School of Pharmacology and Pharmaceutical Sciences, University of California San Diego, Division of Clinical Pharmacy, La Jolla CA, United States of America 7 University of Brescia, ...
BMJ10d
Development and validation of a methotrexate adherence assay
Correspondence to Dr James Bluett, Versus Arthritis Centre for Genetics and Genomics, Centre for Musculoskeletal Research, The University of Manchester, Manchester M13 9PT, UK; ...
BMJ7d
2013 classification criteria for systemic sclerosis: an American college of rheumatology/European league against rheumatism collaborative initiative
41 St. Joseph's Health Care London and University of Western Ontario, London, Ontario, Canada Objective The 1980 American College of Rheumatology (ACR) classification criteria for systemic sclerosis ...
BMJ11d
Instrument selection for the ASAS core outcome set for axial spondyloarthritis
23 National Institute for Health Research, University College London Hospitals Biomedical Research Centre, University College London Hospitals NHS Foundation Trust, London, UK Objectives To define the ...